Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07632820 · ClinicalTrials.gov registry record · Phase 4
Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain
A Phase 4 study, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
NCT07632820: Recruiting Phase 4 study, sponsored by Mayo Clinic.
NCT07632820 is a Phase 4 study that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07632820, a Phase 4 study, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
Study Summary
Chronic thoracic (mid-back) pain can be difficult to treat, and there is limited evidence to guide the use of injection therapies for pain arising from muscles and surrounding soft tissues. Two commonly used treatments are trigger point injections (TPI) and erector spinae plane (ESP) blocks, but no studies have directly compared their effectiveness for chronic thoracic myofascial pain. The purpose of this study is to compare pain relief, physical function, emotional well-being, patient satisfaction, and safety following treatment with either an ESP block or TPI. Participants will be randomly assigned to receive one of the two treatments. Researchers will follow participants for up to 12 weeks after the procedure and collect information through questionnaires and pain assessments.
Interventions
- DRUG Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine
- DRUG Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2029-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07632820
The ClinicalTrials.gov registry entry for NCT07632820 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine is the first listed.
NCT07632820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07632820 about?
NCT07632820 is a clinical study titled "Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain". Chronic thoracic (mid-back) pain can be difficult to treat, and there is limited evidence to guide the use of injection therapies for pain arising from muscles and surrounding soft tissues. Two commonly used treatments are trigger point injections (TPI) and erector spinae plane (ESP) blocks, but no ...
What is the current status of trial NCT07632820?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2026-08-01. Estimated completion is 2029-08-30.
What interventions are being tested in trial NCT07632820?
The interventions under investigation include: Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine (DRUG), Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT07632820?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.